Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Novel Cancer Immune Therapy Developer Oncos Therapeutics Ltd. Appoints Experienced Industry Leader Frans Wuite as President and CEO

HELSINKI, November 9, 2012 /PRNewswire/ --

Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Frans Wuite, M.D., M.B.A, as President and Chief Executive Officer and Pekka Simula, M.Sc. (Tech) as Chief Operating Officer.

Frans Wuite brings more than 25 years of leadership experience that spans from start-up to large international companies within the biopharmaceutical industry to Oncos Therapeutics. Prior to joining Oncos, Wuite served in key leadership roles at companies in rapid growth phases. These included Amgen Europe, where he spearheaded the commercial development and launch of Aranesp that soon became Amgen's biggest product.

Pekka Simula, the founding CEO of Oncos since 2008, successfully built Oncos into a clinical stage company. In his role as COO, Simula will be responsible for the company's overall program management covering research, clinical development, process development, and manufacturing.

Prior to Oncos, Simula was Global Program Manager at Varian Medical Systems responsible for the development and market roll-out of the company's entire oncology product suite.  

About Oncos Therapeutics

Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells, systemic effects through vascular dissemination to metastases, and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens upon oncolysis. In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells. Oncos' oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.

Based on efficacy and safety signals obtained in an Advanced Therapy Access Program (ATAP) with 290 cancer patients, for whom standard of care therapies had failed, CGTG-102 was selected as Oncos' lead product. Clinical experience with 115 CGTG-102-treated patients in ATAP has yielded important information on e.g. optimal dosing and scheduling of the product. CGTG-102 has an orphan indication as its initial target: first line treatment of inoperable Soft Tissue Sarcoma. It is currently in Phase 1 clinical development in Europe and the US. For more information, see http://www.oncos.com.

SOURCE Oncos Therapeutics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
The OpenNebula Project has just announced the Beta release of vOneCloud, a CentOS Linux virtual appliance for vSphere that contains all required OpenNebula services optimized to work on existing VMware vCenter deployments. vOneCloud is for companies that want to create a self-service c...
Code-named “Fox Fur”, the twenty-third release of OpenNebula is available today with complete support to build clouds on existing VMware environments. OpenNebula 4.10 seamlessly integrates vCenter virtualized infrastructures leveraging the advanced features such as vMotion, HA or DRS s...
Let’s say we developed an application and plan to move our app to production on Amazon Elastic Cloud (EC2). Our application, in the form of a webapp, was developed using eclipse and we have tested it on Tomcat running locally. Now, we may want to test our app on an EC2 environment befo...
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software,...
This past week the Appcore team got the opportunity to attend one of the industry’s leading cloud events, Cloud Expo in Santa Clara, CA. We spent a lot of time interacting with attendees at the exhibit portion of the event. As a software company with a sole commitment to CloudStack, we...
As cloud gives an opportunity to businesses to buy services externally – how is cloud impacting your customers? In his General Session at 15th Cloud Expo, Fabio Gori, Director of Worldwide Cloud Marketing at Cisco, provided answers to big questions: Do you see hybrid cloud as where th...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE